Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APOBEC3B-driven mutations negatively regulated by P53 promote tumor progression and immunosuppressive microenvironment in prostate cancer.

Molecular and cellular biochemistry - 1 Feb 2026

Guo Yan, Yu Haodi, Li Xiang, Liu Lina, He Jing, Wang Xin, Zhang Hui, Zhang Qingyu, Fu Jing, Gu Ruixue, Li Hehe, Xu Dengfei, Liu Qinglin, Cang Shun-Dong

Abstract excerpt

APOBEC3B (A3B), a key cytosine deaminase, plays a multifaceted role in the malignant progression of various cancers. However, the precise role of A3B in prostate cancer (PCa) remains largely elusive. This study aimed to investigate the functional significance of A3B in PCa and evaluate its potential as a therapeutic target. We first demonstrated that A3B is significant upregulated in PCa tissues and positively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Movement
Share to Cytidine Deaminase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epithelial-Mesenchymal Transition

Share to Mice, Nude

Share to Minor Histocompatibility Antigens

Share to Neoplasm Proteins

Share to Prostatic Neoplasms

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 41385179
DOI: 10.1007/s11010-025-05442-5
PMCID: PMC12963169

Genes

APOBEC3B
CCK
CD163
PC

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APOBEC3B-driven mutations negatively regulated by P53 promote tumor progression and immunosuppressive microenvironment in prostate cancer.PMID 41385179Read ↗

An overview of the functions and mechanisms of APOBEC3A in tumorigenesisSemantic proximity Read ↗

Potential of APOBEC3B as a therapeutic target and its role in bladder cancer onset and progressionSemantic proximity Read ↗

Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.Semantic proximity Read ↗

APOBEC3A drives metastasis of high-grade serous ovarian cancer by altering epithelial-to-mesenchymal transitionSemantic proximity Read ↗

Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.Semantic proximity Read ↗

Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.Semantic proximity Read ↗

Characterization of RNA editing gene APOBEC3C as a candidate tumor suppressor in prostate cancerSemantic proximity Read ↗

Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer.Semantic proximity Read ↗

Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer.Semantic proximity Read ↗

APOBEC3B, a molecular driver of mutagenesis in human cancersSemantic proximity Read ↗

Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancerSemantic proximity Read ↗

lncRNA MAGI2-AS3 suppresses castration-resistant prostate cancer proliferation and migration via the miR-106a-5p/RAB31 axisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.